30-Jan-2026
Major Insider Makes Bold New Move on Biotech Stock
TipRanks (Tue, 27-Jan 9:01 PM ET)
Biodesix Surpasses Revenue Guidance and Affirms Positive Adjusted EBITDA for Q4 2025
Market Chameleon (Mon, 12-Jan 2:05 AM ET)
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
Globe Newswire (Mon, 12-Jan 6:00 AM ET)
Biodesix Spotlights Advances in Lung and Breast Cancer Diagnostics at Two Major Conferences
Market Chameleon (Thu, 4-Dec 6:20 AM ET)
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings
Globe Newswire (Wed, 3-Dec 8:22 AM ET)
Biodesix Announces Third Quarter 2025 Results and Highlights
Globe Newswire (Mon, 3-Nov 4:01 PM ET)
Biodesix Expands Bio-Rad Partnership to Accelerate High-Sensitivity Cancer Diagnostics
Market Chameleon (Wed, 22-Oct 3:06 AM ET)
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Biodesix trades on the NASDAQ stock market under the symbol BDSX.
As of January 30, 2026, BDSX stock price climbed to $10.17 with 249,248 million shares trading.
BDSX has a beta of 0.56, meaning it tends to be less sensitive to market movements. BDSX has a correlation of 0.01 to the broad based SPY ETF.
BDSX has a market cap of $81.36 million. This is considered a Micro Cap stock.
Last quarter Biodesix reported $22 million in Revenue and -$1.16 earnings per share. This beat revenue expectation by $700,000 and exceeded earnings estimates by $.38.
In the last 3 years, BDSX traded as high as $50.60 and as low as $3.44.
The top ETF exchange traded funds that BDSX belongs to (by Net Assets): VTI, VXF.
BDSX has underperformed the market in the last year with a return of -51.1%, while SPY returned +15.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BDSX shares. However, BDSX has outperformed the market in the last 3 month and 2 week periods, returning +54.8% and +29.1%, while SPY returned +2.1% and 0.0%, respectively. This indicates BDSX has been having a stronger performance recently.
BDSX support price is $8.61 and resistance is $10.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDSX shares will trade within this expected range on the day.